Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 24;24(17):13159.
doi: 10.3390/ijms241713159.

Applicability of Diagnostic Criteria and High Prevalence of Familial Dysbetalipoproteinemia in Russia: A Pilot Study

Affiliations

Applicability of Diagnostic Criteria and High Prevalence of Familial Dysbetalipoproteinemia in Russia: A Pilot Study

Anastasia V Blokhina et al. Int J Mol Sci. .

Abstract

Familial dysbetalipoproteinemia (FD) is a highly atherogenic genetically based lipid disorder with an underestimated actual prevalence. In recent years, several biochemical algorithms have been developed to diagnose FD using available laboratory tests. The practical applicability of FD diagnostic criteria and the prevalence of FD in Russia have not been previously assessed. We demonstrated that the diagnostic algorithms of FD, including the diagnostic apoB levels, require correction, taking into account the distribution of apoB levels in the population. At the same time, a triglycerides cutoff ≥ 1.5 mmol/L may be a useful tool in identifying subjects with FD. In this study, a high prevalence of FD was detected: 0.67% (one in 150) based on the ε2ε2 haplotype and triglycerides levels ≥ 1.5 mmol/L. We also analyzed the presence and pathogenicity of APOE variants associated with autosomal dominant FD in a large research sample.

Keywords: APOE; apolipoprotein B; apolipoprotein E; autosomal dominant; familial dysbetalipoproteinemia; genetic; hyperlipidemia; hyperlipoproteinemia type III; population; remnant lipoproteins.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
The study design: (A) Identification of carriers of the APOE ε2ε2 haplotype, assessment of the sensitivity and specificity of biochemical FD criteria, and prevalence of FD; (B) Identification of previously reported and new APOE variants associated with the autosomal dominant FD, analysis of the genotype–phenotype relationship.

References

    1. Blum C.B. Type III hyperlipoproteinemia: Still worth considering? Prog. Cardiovasc. Dis. 2016;59:119–124. doi: 10.1016/j.pcad.2016.07.007. - DOI - PubMed
    1. Marais A.D., Solomon G.A., Blom D.J. Dysbetalipoproteinaemia: A mixed hyperlipidaemia of remnant lipoproteins due to mutations in apolipoprotein E. Crit. Rev. Clin. Lab. Sci. 2014;51:46–62. doi: 10.3109/10408363.2013.870526. - DOI - PubMed
    1. Smelt A.H.M., De Beer F. Apolipoprotein E and familial dysbetalipoproteinemia: Clinical, biochemical, and genetic aspects. Semin. Vasc. Med. 2004;4:249–257. doi: 10.1055/s-2004-861492. - DOI - PubMed
    1. Mahley R.W., Weisgraber K.H., Huang Y. Apolipoprotein E: Structure determines function, from atherosclerosis to Alzheimer’s disease to AIDS. J. Lipid. Res. 2009;50:183–188. doi: 10.1194/jlr.R800069-JLR200. - DOI - PMC - PubMed
    1. Blokhina A.V., Ershova A.I., Meshkov A.N., Drapkina O.M. Familial dysbetalipoproteinemia: Highly atherogenic and underdiagnosed disorder. Cardiovasc. Ther. Prev. 2021;20:2893. doi: 10.15829/1728-8800-2021-2893. - DOI

LinkOut - more resources